News is out DNAP and ORCHID:
Original Message -----
From: alert@stocktribe.com
To: alert@stocktribe.com
Sent: Thursday, October 05, 2000 11:47 PM
Subject: Alert
STOCKTRIBE.COM------ALERT------DALLAS, TX------CALGARY, AB
stocktribe.com members, following is yet further evidence that DNAP Print Genomics is preparing for bigger and better things. stocktribe.com reconfirms it's commitment to only providing quality, substantive and relevant investment information. We have received a lot of feedback from many of you on this particular company. To satisfy all that have inquired we are making every effort to keep you abreast of all developments at DNA Print Genomics. As always we encourage your feedback at info@stocktribe.com
__________________________________________________________________________________________________________
ORCHID AND DNAPRINT ANNOUNCE PURCHASE OF SNPSTREAM™ 25K GENOTYPING SYSTEM
PRINCETON, N.J., and SARASOTA, FL., Oct. 6, 2000 – Orchid BioSciences, Inc. (Nasdaq: ORCH) and DNAPrint genomics, Inc, today announced that DNAPrint has agreed to purchase Orchid’s SNPstream™ 25K system for industrial-scale single nucleotide polymorphism (SNP) scoring. DNAPrint researchers will conduct high throughput genotyping using Orchid’s SNPstream 25K platform and SNPware™ kits incorporating the company’s proprietary SNP-IT™ primer extension biochemistries and software. Under terms of the agreement, DNAPrint will make an upfront payment to Orchid and will purchase SNPware consumables on a per unit basis. Other details of the agreement were not disclosed.
"Accelerating efforts to unravel medically useful applications of genetic diversity are driving interest in SNP scoring. Orchid has already placed a number of its high throughput SNPstream 25K systems with leading pharmaceutical and agricultural companies," said Russell Granzow, vice president of marketing and business development of Orchid. "We are delighted to now add an emerging innovator in the development of complex genetic analytics like DNAPrint Genomics to our growing list of customers."
Orchid’s expanding line of SNPstream instruments and SNPware consumables is designed to enable researchers to rapidly analyze SNPs, the most common form of genetic variation, in order to identify their role in disease susceptibility and drug treatment response. SNPstream 25K incorporates the accuracy, robustness and cost effectiveness of Orchid’s proprietary SNP-IT technology in a fully automated, high throughput assay platform that can analyze up to 25,000 SNPs per day. The SNPstream system includes easy-to-use SNP-IT-based genotyping kits and associated software.
"As a young company aiming to build a leadership position in the rapidly emerging field of personalized medicine and pharmacogenetics, we wanted to acquire a leading SNP genotyping technology," said Tony Frudakis, Ph.D., president of DNAPrint. "The integrated solution provided by the SNPstream 25K system provides the combination of accuracy, throughput, flexibility and cost effectiveness our business demands."
Orchid BioSciences, Inc. is a provider of products, services and technologies for SNP scoring and genetic diversity analyses. Orchid has developed SNP-IT, its proprietary SNP analysis technology, and markets SNPstream instruments and SNPware consumables that rapidly generate highly accurate, cost effective SNP information. Orchid also provides high throughput SNP scoring services to pharmaceutical, agricultural and academic customers through its MegaSNPatron™ facility, and DNA testing through its GeneScreen facilities, which conduct paternity, forensics and transplantation testing.
DNAPrint genomics, Inc. provides practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification. DNAPrint genomics Inc. was founded by a group of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. For more information about the company, please visit www.stocktribe.com
__________________________________________________________________________________________________________________________
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act.
stocktribe.com has not been compensated for this summary, nor do we hold a position in this company.
If you would like to unsubscribe, please reply to this email with "unsubscribe" written in the subject line.
Favorite BoardMarks / BICO / THE NAP HEADS BOARD / DNAP
